JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B6032 CB-5083

Target: p97

Summary: p97 inhibitor

insoluble in H2O; ≥20.65 mg/mL
A3010 MK-2206 dihydrochloride
21 Citation

Target: Akt

Summary: Akt1/2/3 inhibitor

insoluble in EtOH; ≥12.01 mg/mL
A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A3020 (R)-Crizotinib
2 Citation

Target: c-MET

Summary: C-MET/ALK inhibitor,potent and ATP-competitve

insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL
A4090 JNJ-26481585
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Potent HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥19.2 mg/mL
A4061 IPI-504 (Retaspimycin hydrochloride)
3 Citation

Target: HSP90

Summary: Hsp90 inhibitor,novel, potent,selective

≥26.1 mg/mL
A4064 NVP-BEP800

Target: HSP90

Summary: Oral Hsp90β inhibitor, novel, fully synthetic
A4112 Barasertib (AZD1152-HQPA)
3 Citation

Target: Aurora Kinases

Summary: Aurora Kinase B inhibitor, Potent and selective

≥25.4 mg/mL
A4127 GSK1070916

Target: Aurora Kinases

Summary: Aurora B/C inhibitor

≥25.4 mg/mL
A4330 Isotretinoin

Target: RARs

Summary: Dopamine β-hydroxylase activator

insoluble in H2O; ≥13.8 mg/mL